Abstract
Objective The T1GER study showed that treatment with the TNFα inhibitor golimumab in recently diagnosed type 1 diabetes patients showed better preservation of endogenous insulin production than placebo. However, considerable variation was observed among subjects. Therefore, a range of biomarkers were investigated for their potential to predict treatment response to golimumab.
Research Design and Methods Baseline blood samples from 79 subjects were tested for autoantibodies, microRNA, metabolites, lipids, inflammatory proteins, and clinical chemistry. Univariate analysis was used to identify biomarkers that correlated with C-peptide change. Multivariate analysis was performed to establish a biomarker algorithm predicting the C-peptide response during the study.
Results Multivariate analysis showed that baseline metabolites and miRNAs best predicted C- peptide responses both for placebo and treatment arms. Lipids, and inflammatory proteins were moderately predictive, whereas autoantibodies and clinical chemistry showed little predictive value.
An optimal model combining selected clinical variables and metabolites showed a correlation between predicted and observed C-peptide responses for the overall study up to 52 weeks, with an R2 of 0.85. An LOOCV model was developed as a surrogate validation test, resulting in an R2 of 0.69 overall, and an R2 of 0.76 specifically predicting C-peptide responses at week 38.
Conclusions The exploratory analysis of the T1GER study resulted in a set of baseline biomarkers with promising performance in predicting future C-peptide responses during the study. If validated in independent cohorts, these prognostic and predictive biomarkers and algorithm carry significant translational impacts that can assist clinicians in making treatment decisions.
Competing Interest Statement
All authors were paid employees by Janssen R&D
Clinical Trial
NCT02846545
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The current manuscript is an analysis of samples derived from Study NCTNCT02846545, reported by Quattrin et al NEJM 2020. Such sample analysis was included in the protocol and was approved by the IRBs of all participating locations. University at Buffalo John R. Oishei Childrens Hospital Buffalo NY University of Florida Gainesville. University of Colorado Anschutz Medical Campus Aurora. Emory University School of Medicine Atlanta
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
